---
title: "DUALITYBIO-B has been included in the Hang Seng Composite Index constituents"
description: "DUALITYBIO-B announced that starting from September 8, 2025, it will be included in the Hang Seng Composite Index constituents and the list of eligible stocks under the Hong Kong Stock Connect. This m"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256271226.md"
published_at: "2025-09-07T11:04:02.000Z"
---

# DUALITYBIO-B has been included in the Hang Seng Composite Index constituents

> DUALITYBIO-B announced that starting from September 8, 2025, it will be included in the Hang Seng Composite Index constituents and the list of eligible stocks under the Hong Kong Stock Connect. This move indicates the capital market's recognition of the company and is expected to expand the investor base and increase the trading liquidity of its shares

According to the announcement from DUALITYBIO-B (09606), starting from September 8, 2025, the company's shares will (i) be included in the Hang Seng Composite Index constituents by Hang Seng Indexes Company Limited and (ii) be added to the list of eligible stocks under the Stock Connect program.

The inclusion of shares in the Hang Seng Composite Index and the eligible securities for Stock Connect represents a high recognition of the company's performance and value by the capital market, allowing qualified investors in mainland China to directly invest in shares listed on Hong Kong Exchanges and Clearing Limited through the Shanghai Stock Exchange. This inclusion is expected to further expand the company's investor base and is likely to increase the trading liquidity of the shares

### Related Stocks

- [09606.HK - DUALITYBIO-B](https://longbridge.com/en/quote/09606.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 早盘趋势｜映恩生物资金再收缩，板块变盘机会在路上？ | 12 月 29 日映恩生物 -B 整日承压，资金持续围绕 10.3-10.5 元反复观望。生物医药板块整体陷入缩量盘整，行业缺乏重磅利好，投资者短线观望为主。MACD 短期均线死叉信号持续，弱势技术格局暂难改观。头部药企未有新药上市或合作订 | [Link](https://longbridge.com/en/news/270968880.md) |
| 汇丰缩减其美国债务资本市场团队 | 汇丰缩减美国债务资本市场团队 | [Link](https://longbridge.com/en/news/276403741.md) |
| Coor 2026 年资本市场日邀请函 | Coor Service Management Holding AB（公开发行）宣布将于 2026 年 3 月 19 日在瑞典索尔纳的总部举行资本市场日活动。该活动将于中欧时间 13:00 至 17:00 举行，届时将由总裁兼首席执行官 O | [Link](https://longbridge.com/en/news/276407389.md) |
| 据报道，汇丰在削减成本的行动中缩减了其美国债务资本市场团队 | 汇丰据报道在削减成本的过程中裁减了美国债务资本市场团队 | [Link](https://longbridge.com/en/news/276411536.md) |
| 3.5 亿首付款、总额达 85 亿美元！信达生物与礼来合作布局肿瘤免疫新药研发 | 信达生物与礼来达成突破性合作，将联合开发肿瘤及免疫新药。此次交易预付款 3.5 亿美元，总额最高达 85 亿美元。双方摒弃传统授权，采用从零开始的共同研发模式，标志着中国药企创新力获全球顶尖药企深度认可，开启全球战略协作新篇章。 | [Link](https://longbridge.com/en/news/275269682.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.